VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 560 filers reported holding VALEANT PHARMACEUTICALS INTL in Q1 2015. The put-call ratio across all filers is 2.18 and the average weighting 1.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $1,324,000 | -83.0% | 120,000 | +120.1% | 0.05% | -80.9% |
| Q4 2014 | $7,801,000 | +9.1% | 54,509 | 0.0% | 0.27% | +13.3% |
| Q3 2014 | $7,152,000 | +427.8% | 54,509 | +407.3% | 0.24% | +336.4% |
| Q2 2014 | $1,355,000 | -57.2% | 10,745 | -55.2% | 0.06% | -43.9% |
| Q1 2014 | $3,165,000 | +12.3% | 24,010 | 0.0% | 0.10% | +19.5% |
| Q4 2013 | $2,819,000 | – | 24,010 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 5,577,892 | $994,984,000 | 31.62% |
| Ruane, Cunniff & Goldfarb | 33,922,192 | $6,051,041,000 | 31.06% |
| LeVasseur Capital Partners LLC | 162,394 | $28,968,000 | 29.76% |
| FARLEY CAPITAL L.P. | 192,130 | $34,272,000 | 27.18% |
| Pershing Square Capital Management | 19,473,933 | $3,473,760,000 | 24.90% |
| Arrow Capital Management, LLC | 109,461 | $19,525,000 | 16.53% |
| Marble Arch Investments | 1,196,900 | $213,503,000 | 16.43% |
| Tesuji Partners | 1,368,040 | $244,414,000 | 15.82% |
| ValueAct Holdings | 14,994,261 | $2,674,676,000 | 15.55% |
| Hound Partners | 3,898,648 | $695,441,000 | 15.04% |